A New Mutational and Epigenetic Signature to Predict Early OPSCC Relapse
Conditions: Oropharyngeal Squamous Cell Carcinoma Sponsors: Centro di Riferimento Oncologico - Aviano Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 18, 2023 Category: Research Source Type: clinical trials
Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer
Conditions: Metastatic Esophageal Squamous Cell Carcinoma Interventions: Drug: TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors （Sintilimab） Sponsors: Qingdao Central Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials
Pilot Trial of MR-guided Adaptive Radiotherapy Boost for HNSCC
Conditions: Squamous Cell Carcinoma; Head and Neck Cancer Interventions: Radiation: Intensity-modulated radiotherapy; Other: Magnetic Resonance Guidance Sponsors: H. Lee Moffitt Cancer Center and Research Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials
European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]
Conditions: Squamous Cell Carcinoma of Head and Neck; Hypopharyngeal Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma Stage III; Laryngeal Squamous Cell Carcinoma Stage IV; Squamous Cell Carcinoma of Larynx; Squamous Cell Carcinoma of the Larynx; Squamous Cell Carcinoma of the Larynx Stage III; Squamous Cell Carcinoma of the Larynx Stage IV; Laryngeal Squamous Cell Carcinoma; Laryngectomy; Status; Laryngeal Cancer; Laryngeal Neoplasms Interventions: Biological: KEYTRUDA ® Sponsors: University of Leipzig; University of G öttingen; University of Jena; University of Cologne; University of Ulm; University of Regens...
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)
Conditions: Oral Cancer; PD-1 Interventions: Drug: PD-1 with chemotherapy; Procedure: upright surgery Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 14, 2023 Category: Research Source Type: clinical trials
A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma.
Conditions: Oral Squamous Cell Carcinoma Interventions: Drug: Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy Sponsors: Xuekui Liu Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 13, 2023 Category: Research Source Type: clinical trials
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma Interventions: Drug: volrustomig Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 13, 2023 Category: Research Source Type: clinical trials
Gut and Tumor Microbiome in Patients With Advanced ER-positive and HER2-negative Breast Cancer or Advanced Melanoma Undergoing PD-1 Checkpoint Inhibitor Therapy.
Conditions: Breast Cancer; Melanoma Interventions: Other: Observation Sponsors: BioCorteX Inc; Tempus Labs Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 10, 2023 Category: Research Source Type: clinical trials
Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in ESCC.
Conditions: Esophageal Squamous Cell Carcinoma; Immunotherapy; Chemotherapy Sponsors: Guangdong Provincial People ' s Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 9, 2023 Category: Research Source Type: clinical trials
Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in ESCC
Conditions: Esophageal Squamous Cell Carcinoma; Immunotherapy; Chemotherapy Sponsors: Guangdong Provincial People ' s Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 9, 2023 Category: Research Source Type: clinical trials
PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma
Conditions: Squamous Cell Carcinoma of Head and Neck; Neoadjuvant Therapy; Immunotherapy Sponsors: Xijing Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 9, 2023 Category: Research Source Type: clinical trials
Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Advanced Squamous Cell Lung Cancer
Conditions: Advanced Lung Squamous Cell Carcinoma Interventions: Radiation: low-dose radiation therapy and stereotactic body radiation therapy; Drug: chemotherapy; Drug: Sintilimab Sponsors: Sichuan University; Innovent Biologics (Suzhou) Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials
Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab vs. Sintilimab + Chemotherapy in Advanced Squamous Cell Lung Cancer
Conditions: Advanced Lung Squamous Cell Carcinoma Interventions: Radiation: low-dose radiation therapy and stereotactic body radiation therapy; Drug: chemotherapy; Drug: Sintilimab Sponsors: Sichuan University; Innovent Biologics (Suzhou) Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials
Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
Conditions: Esophageal Squamous Cell Carcinoma Interventions: Drug: Tirelizumab; Drug: Nab paclitaxel; Drug: Carboplatin; Radiation: Radiotherapy Sponsors: Ruijin Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials
A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002)
Conditions: Tumor Infiltrating Lymphocytes; Safety; Melanoma; Efficacy; Adverse Drug Event Interventions: Biological: GC101 TIL Sponsors: Shanghai Juncell Therapeutics Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials
